Trial Profile
A Phase II Study of Bevacizumab (Avastin) in Combination with Standard Second line chemotherapy (Docetaxel Or Pemetrexed) in Patients with Non-Squamous Non-Small-Cell Lung Cancer previously Treated with chemotherapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ADOPT
- 24 Apr 2019 Status changed from recruiting to discontinued.
- 06 Feb 2012 New trial record